Blog

Olubukola Ayodele/LinkedIn

May 31, 2025, 04:50

Olubukola Ayodele: Heading to ASCO25

Olubukola Ayodele, Consultant Medical Oncologist at the University Hospitals of Leicester NHS Trust, posted on LinkedIn:

“As I head to Chicago for ASCO25, I’m filled with anticipation not just for the data, but for what it will mean at the bedside.

This year’s congress is brimming with potentially practice-informing trials that could further personalize how we treat breast cancer.

Here are a few I’m particularly watching:

INAVO120 (Final OS Analysis)
This pivotal Phase 3 trial explores the triplet of palbociclib, inavolisib (a PI3Kα inhibitor) and fulvestrant versus the standard of care in HR+/HER2-, PIK3CA-mutant advanced breast cancer. Will targeting PI3Kα earlier and more intensively in this endocrine resistant population improve survival?

DESTINY-BREAST 09
T-DXd + pertuzumab vs standard taxane + trastuzumab + pertuzumab in first-line HER2+ metastatic breast cancer. Could this trial shift ADCs into the upfront setting and replace conventional chemotherapy as the default?

ASCENT-04
Sacituzumab govitecan combined with pembrolizumab in first-line metastatic TNBC. This antibody-drug conjugate and immunotherapy combo may redefine first-line TNBC strategy for PD-L1 positive patients, an area where we urgently need better options.

SERENA-6
A novel SERD, camizestrant in combination with CDK 4 /6 inhibitors, in first-line endocrine-sensitive HR+ HER2- metastatic breast cancer. Could this switch when ESR1-mutation is detected, offer improved disease control over aromatase inhibitors and herald a shift in the first-line endocrine landscape?

COMPASSHER2
An adaptive trial evaluating escalation and de-escalation in HER2+ early breast cancer. Importantly, it also deepens our understanding of HER2-low and biomarkers of response.

NEOCARHP and NEOSTAR
Exploring response-adaptive neoadjuvant strategies and chemo-sparing approaches: very critical as we refine what pCR truly predicts across subtypes.

As a breast oncologist, I see how trial outcomes become real-world decisions : improved survival, fewer side effects and smarter sequencing for patients. I’ll be sharing reflections throughout the week.

Let’s keep pushing for data that drives change; not just in treatment, but in equity and access too.”

More posts featuring Olubukola Ayodele.